nicotine has been researched along with allopurinol in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cho, CH; Ogle, CW; Qiu, BS | 1 |
| Obach, RS | 1 |
| Chowdhury, P; Walker, A | 1 |
| Anuvarbekova, A; Ercan, ZS; Fincan, GS; Ozger, SI; Sarioglu, Y; Utkan, T; Vural, IM | 1 |
| Checa-Andrés, MD; Esparza-Martín, N; García-Cantón, C; Guerra-Rodríguez, R; Ramírez-Puga, A; Suria-González, S | 1 |
| Choudhary, MI; Hayat, M; Khan, KM; Khan, M; Malik, R; Saied, S; Salar, U; Zafar, H | 1 |
| Areola, ED; Dangana, EO; Olaniyi, KS; Olatunji, LA; Omolekulo, TE; Soladoye, AO | 1 |
20 other study(ies) available for nicotine and allopurinol
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Nicotine and gastric ulcers in stress.
Topics: Animals; Female; Free Radicals; Gastric Mucosa; Male; Nicotine; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Stomach Ulcer; Stress, Physiological; Xanthine Oxidase | 1993 |
Potent inhibition of human liver aldehyde oxidase by raloxifene.
Topics: Aldehyde Oxidase; Benzaldehydes; Enzyme Inhibitors; Humans; In Vitro Techniques; Kinetics; Liver; Nicotine; Oxidation-Reduction; Phthalazines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Xanthine Oxidase | 2004 |
A cell-based approach to study changes in the pancreas following nicotine exposure in an animal model of injury.
Topics: Allopurinol; Amylases; Animals; Cell Division; Cell Line, Tumor; Cell Survival; Enzyme Activation; Free Radical Scavengers; Free Radicals; Hydrogen Peroxide; In Vitro Techniques; Lipid Peroxidation; Malondialdehyde; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Microscopy, Fluorescence; Nicotine; Oxidative Stress; Pancreas; Rats; Signal Transduction; Smoking | 2008 |
Investigation of enhancement effects of nicotine on cholinergic neurotransmission in isolated rabbit gastric fundus: role of antioxidants.
Topics: Acetylcholine; Allopurinol; Animals; Antioxidants; Atropine; Cholinergic Fibers; Deferoxamine; Electric Stimulation; Gastric Fundus; In Vitro Techniques; Mannitol; Muscle Contraction; Muscle, Smooth; Neostigmine; Nicotine; Rabbits; Reactive Oxygen Species; Synaptic Transmission; Tetrodotoxin | 2010 |
Effect of allopurinol on smoking.
Topics: Acetylcholine; Allopurinol; Benzazepines; Brain Chemistry; Bupropion; Causality; Comorbidity; Diabetic Nephropathies; Humans; Hypoxanthine; Molecular Structure; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Structure-Activity Relationship; Varenicline; Xanthine Oxidase | 2013 |
Xanthine oxidase inhibitory activity of nicotino/isonicotinohydrazides: A systematic approach from in vitro, in silico to in vivo studies.
Topics: Computer Simulation; Enzyme Inhibitors; In Vitro Techniques; Kinetics; Nicotine; Structure-Activity Relationship; Xanthine Oxidase | 2017 |
Sodium acetate protects against nicotine-induced excess hepatic lipid in male rats by suppressing xanthine oxidase activity.
Topics: Animals; Area Under Curve; Fatty Acids, Nonesterified; Glucose Tolerance Test; Insulin Resistance; Lipid Peroxidation; Lipids; Liver; Male; Nicotine; Protective Agents; Rats; Rats, Wistar; ROC Curve; Sodium Acetate; Triglycerides; Xanthine Oxidase | 2020 |